Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Wuxi Biologics (Cayman) ( (HK:2269) ) has issued an update.
WuXi Biologics announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where it will present on its business operations. The company reported a strong business and financial position in 2024 with 151 new projects, totaling 817 projects, and significant revenue growth expectations for 2025. The company also highlighted its accelerated development timeline for monoclonal antibodies and anticipates profit generation from its Ireland site.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a company in the biotechnology industry, specializing in providing comprehensive biologics discovery, development, and manufacturing services. The company focuses on monoclonal antibodies and other biological products, serving a global market.
YTD Price Performance: 1.39%
Average Trading Volume: 5,801
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.07B
For a thorough assessment of 2269 stock, go to TipRanks’ Stock Analysis page.
